Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Zinc finger protein 92 homolog (ZFP92) is a KRAB domain-containing transcription factor that binds to DNA, modulating gene expression and participating in the silencing of B1/Alu SINE transposable elements[4]. It is predicted to regulate transcription, particularly through RNA polymerase II, and is active in the nucleus[2]. ZFP92 belongs to the large family of zinc finger proteins, which play critical roles in gene regulation, cell differentiation, apoptosis, and immune response but most are not themselves direct therapeutic targets[1][2]. There is limited evidence connecting ZFP92 directly to disease mechanisms, though genetic analyses have associated it with adrenoleukodystrophy[2]. No marketed drugs, biomarkers, or drug mechanisms currently target ZFP92.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Zinc finger protein 92 homolog (ZFP92).